Annals of Cancer Research and Therapy
Online ISSN : 1880-5469
Print ISSN : 1344-6835
ISSN-L : 1344-6835
A case of renal salt-wasting syndrome induced by cisplatin and 5-FU during treatment of esophageal squamous cell carcinoma
Dai ShimizuMitsuro Kanda Masahiko KoikeShinichi UmedaFuminori SonoharaHideki TakamiYoshikuni InokawaNorifumi HattoriMasamichi HayashiChie TanakaDaisuke KobayashiSuguru YamadaGoro NakayamaMichitaka FujiwaraYasuhiro Kodera
Author information
JOURNAL FREE ACCESS

2019 Volume 27 Issue 2 Pages 64-66

Details
Abstract

The combination regimen of cisplatin (CDDP) and fluorouracil (5-FU) (FP) is a standard regimen for definitive chemoradiotherapy, neoadjuvant chemotherapy, and for treatment of unresectable or recurrent esophageal squamous cell carcinoma (ESCC). Here, we report a patient with FP-induced renal salt-wasting syndrome (RSWS) who presented with severe hyponatremia with disturbance of consciousness and was admitted to the intensive care unit (ICU). A 66-year-old man with recurrent ESCC was admitted and started on chemotherapy with FP. From day 3 of the first course of FP, he presented with anorexia and vomiting (grade 3). At day 6, he experienced disturbance of consciousness and blood test showed severe hyponatremia (sodium (Na): 119 mmol/L) accompanied with excessive urinary excretion of Na (181 mmol/L). He was diagnosed with RSWS because of CDDP and was transferred to the ICU. Through intensive monitoring and 3% NaCl infusion, serum Na level and symptoms recovered with no sequelae and he was discharged from the ICU after a 4-day stay.

RSWS is sometimes difficult to diagnose because of its low recognition and is misdiagnosed as the syndrome of inappropriate secretion of antidiuretic hormone. During chemotherapy with platinum-based agents, RSWS should be kept in mind as a disorder that causes hyponatremia.

Content from these authors
© 2019 by The Japanese Society of Strategies for Cancer Research and Therapy
Previous article Next article
feedback
Top